506-31-0

Usage

Uses

Used in Pharmaceutical Applications:
9-Eicosenoic acid is used as a potential biomarker for the diagnosis and monitoring of certain diseases, such as autism and cardiovascular diseases. Its identification in biological samples can aid in early detection and risk assessment, contributing to timely intervention and treatment strategies.
Used in Nutraceutical Applications:
9-Eicosenoic acid is used as a dietary supplement for its health benefits, including its anti-inflammatory and antioxidant properties. It supports lipid metabolism and reduces the risk of cardiovascular diseases, promoting overall health and well-being.
Used in Cosmetic Industry:
9-Eicosenoic acid is used as a moisturizing and nourishing agent in cosmetic products. When applied topically, it helps maintain skin hydration, providing a smooth and healthy appearance.
Used in Functional Foods:
9-Eicosenoic acid can be incorporated into functional foods and beverages as a health-promoting ingredient. Its presence in these products can contribute to the maintenance of optimal health and the reduction of disease risk, particularly cardiovascular diseases.

InChI:InChI=1/C20H38O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h11-12H,2-10,13-19H2,1H3,(H,21,22)/b12-11+

Upstream product

• 116557-14-3 eicos-9c-enoic acid ethyl ester 
• 112-44-7 undecylaldehyde 
• 8001-23-8 safflower oil 
• 29204-02-2 gadoleic acid 
• 17696-11-6 8-bromooctanoic acid 
• 67810-35-9 cis-Eicos-9-enoic acid methyl ester 
• 1309764-97-3 methyl icos-9-ynoate 
• 26825-92-3 methyl 8-bromooctanoate 

Downstream Products

• 62133-71-5 eicos-9t-enoic acid 
• 60-33-3 linoleic acid 

Relevant academic research and scientific papers

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

Neuropathic pain (NP) is a complex chronic pain state with a prevalence of almost 10% in the general population. Pharmacological options for NP are limited and weakly effective, so there is a need to develop more efficacious NP attenuating drugs. Activation of the type 1 lysophosphatidic acid (LPA1) receptor is a crucial factor in the initiation of NP. Hence, it is conceivable that a functional antagonism strategy could lead to NP mitigation. Here we describe a new series of LPA1 agonists among which derivative (S)-17 (UCM-05194) stands out as the most potent and selective LPA1 receptor agonist described so far (Emax = 118%, EC50 = 0.24 μM, KD = 19.6 nM; inactive at autotaxin and LPA2-6 receptors). This compound induces characteristic LPA1-mediated cellular effects and prompts the internalization of the receptor leading to its functional inactivation in primary sensory neurons and to an efficacious attenuation of the pain perception in an in vivo model of NP.

NEW CONJUGATED LINOLENIC ACIDS AND METHODS FOR COMMERCIAL PREPARATION AND PURIFICATION

A method for the preparation and purification of conjugated linolenic acids is described. The method comprises blending a mixture of vegetable oils and or fats including various concentrations of alpha or gamma and or both linolenic acids with a base. The method transforms approximately over two thirds of α-linolenic acid (9Z,12Z,15Z-octadecatrienoic acid) into 9Z,11E,15Z-octadecatrienoic acid and 9Z,13E,15Z-octadecatrienoic acid. The method also transforms gamma-linolenic acid (6Z,9Z,12Z-octadecatrienoic acid) into 6Z,8E,15Z-octadeccatrienoic acid and 6Z,10E,12Z-octadecatrienoic acid. In all cases, geometrical isomers and fully conjugated isomers are also produced.